Clinical Trial Update: SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SPI-1005 addressing prevention and treatment of chemotherapy-induced hearing loss, with related conditions including lung and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Hearing Loss
• Lung Cancer
• Neuropathy
• Ototoxicity
• Tinnitus

Drugs mentioned

• SPI-1005

Snippet

Sponsor: Sound Pharmaceuticals, Incorporated | Conditions: Lung Cancer, Head and Neck Cancer | Phase 2 | Status: UNKNOWN